Navigation Links
Medarex Announces Presentations at Annual Meeting of the American Society of Clinical Oncology
Date:4/29/2008

l time on Sunday, June 1,

2008.

-- "Effect of a fully human anti-CD70 antibody on apoptosis and

dephosphorylation of MAPK proteins in chronic lymphocytic leukemia"

(Abstract #3073, Developmental Therapeutics: Immunotherapy

Session) -- Poster presentation from 2:00 p.m. to 6:00 p.m. local time

on Sunday, June 1, 2008.

More information about the ASCO Annual Meeting may be found at http://www.asco.org.

About Medarex

Medarex is a biopharmaceutical company focused on the discovery, development and potential commercialization of fully human antibody-based therapeutics to treat life-threatening and debilitating diseases, including cancer, inflammation, autoimmune disorders and infectious diseases. Medarex applies its UltiMAb(R) technology and product development and clinical manufacturing experience to generate, support and potentially commercialize a broad range of fully human antibody product candidates for itself and its partners. More than 40 of these therapeutic product candidates derived from Medarex technology are in human clinical testing or have had INDs submitted for such trials, with seven of the most advanced product candidates currently in Phase 3 clinical trials or the subject of regulatory applications for marketing authorization. Medarex is committed to building value by developing a diverse pipeline of antibody products to address the world's unmet healthcare needs. For more information about Medarex, visit its website at http://www.medarex.com.

Medarex(R), the Medarex logo and UltiMAb(R) are registered trademarks of Medarex, Inc. All rights are reserved.


'/>"/>
SOURCE Medarex, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Medarex Reports Interim Data from Ongoing Ipilimumab Combination Phase 1 Studies in Prostate Cancer at American Association for Cancer Research Meeting
2. Medarex Announces Ipilimumab Program Continues to Move Forward
3. Medarex to Receive Milestone Payment from Amgen
4. Medarex Announces Allowance of Investigational New Drug Applications for Wholly Owned Fully Human Anti-CD19 Antibody, MDX-1342
5. Alexza Announces Positive Phase 1 Results With AZ-007 (Staccato(R) Zaleplon)
6. Nuvelo Announces Positive Proof-of-Concept Data With Anticogulant NU172
7. XTENT Announces First Quarter 2008 Financial Results
8. Neuralstem Announces Issuance of Core Technology Patent in Europe
9. ROXRO PHARMA Announces Positive Clinical Proof of Concept Results for Novel Intranasal Migraine Treatment
10. PulmoBioTech Announces Details of Its Regulatory Approval Experiments
11. Lixte Biotechnology Holdings Announces That Anti-Cancer Activity Against Glioblastoma in an Animal Model Was Reported at the Annual Meeting of the American Association of Cancer Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... Cyberonics, Inc. (NASDAQ: CYBX ), a ... of epilepsy, today announced it will participate in the 33 ... 14, 2015, in San Francisco . ... Officer, will speak at 11:00 AM Pacific Time.  A live ... on the Investor Relations link on the Cyberonics home page ...
(Date:12/22/2014)... PALO ALTO, Calif. , Dec, 22, 2014 ... of a Phase 2a study of lonafarnib in ...  The study was conducted at the National Institutes ... Bethesda, Maryland .  The double-blinded, randomized, placebo-controlled, ... 100 mg twice daily and 200 mg twice ...
(Date:12/19/2014)... Friday, December 19 edition of USA ... features Konica Minolta, the company announced today. The supplement will focus ... organizations. In addition to the print section that ... New York , Chicago , ... Minneapolis and San Francisco , a ...
Breaking Medicine Technology:Eiger Bio Announces Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib - Results Presented at American Association for the Study of Liver Diseases (AASLD) Meeting 2Eiger Bio Announces Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib - Results Presented at American Association for the Study of Liver Diseases (AASLD) Meeting 3USA Today Supplement Featuring Konica Minolta Focuses on Impact of Healthcare IT 2
... Feb. 16, 2012 Mylan Inc. (Nasdaq: ... ) today announced that Meridian Medical Technologies, a Pfizer ... and Sanofi-Aventis that will resolve pending patent litigation related ... epinephrine auto-injector known as e-cue™, which will be manufactured ...
... Acknowledging the importance of dedicated information management systems ... demonstrate the most recent version of its MOSAIQ® ... and Management Systems Society,s 2012 conference (HIMSS12), Feb. ... is a comprehensive OIS that centralizes traditional radiation ...
Cached Medicine Technology:Mylan and Pfizer Announce Epinephrine Auto-injector Settlement Agreement 2Mylan and Pfizer Announce Epinephrine Auto-injector Settlement Agreement 3Mylan and Pfizer Announce Epinephrine Auto-injector Settlement Agreement 4Mylan and Pfizer Announce Epinephrine Auto-injector Settlement Agreement 5Elekta Highlights Latest Version of MOSAIQ Oncology Information System at HIMSS12 Meeting 2
(Date:12/24/2014)... Dennis Thompson HealthDay Reporter ... news about the experimental Ebola vaccine that U.S. officials are ... shows a precursor of that vaccine produced a safe and ... the vaccine, when given to more than 100 Ugandans in ... blood cells that could potentially protect a person against infection ...
(Date:12/24/2014)... -- Longer and colder body cooling does not reduce the ... a lack of oxygen, a new study finds. The ... -- called hypoxic ischemic encephalopathy -- can be reduced by ... for 72 hours, experts say. Research has shown that ... this study examined if the same would be true in ...
(Date:12/24/2014)... News) -- Though most patients with obsessive-compulsive disorder (OCD) ... 10 percent to 20 percent have a form of ... say. However, patients with this so-called "refractory OCD" ... of brain surgery that disables certain brain networks believed ... between patients most likely to benefit from the surgery, ...
(Date:12/24/2014)... TUESDAY, Dec. 23, 2014 (HealthDay News) -- If you ... off if you are not treated by a cardiologist, ... actually improved when cardiologists left town for annual professional ... with cardiac arrest who were admitted to a teaching ... days, but 70 percent died when these meetings were ...
(Date:12/22/2014)... December 22, 2014 As part ... senior care service in San Diego and ... of its senior care team with ongoing online ... Golden Care is provided by Caregiverlist®. Caregiverlist® ... caregivers with the most reliable eldercare options, highest ...
Breaking Medicine News(10 mins):Health News:Early Study Offers Hope for an Ebola Vaccine 2Health News:Early Study Offers Hope for an Ebola Vaccine 3Health News:Early Study Offers Hope for an Ebola Vaccine 4Health News:Greater Cooling of Oxygen-Deprived Infants Fails to Improve Survival 2Health News:Scans May Spot People Who'll Benefit From Surgery for OCD 2Health News:When Heart Docs Are Away, Their High-Risk Patients May Fare Better 2Health News:When Heart Docs Are Away, Their High-Risk Patients May Fare Better 3Health News:Golden Care Partners with Nationally Recognized Caregiver Training Service 2
... boceprevir has been available since the middle of 2011 ... 1. In an early benefit assessment pursuant to the ... Products" (AMNOG), the German Institute for Quality and Efficiency ... whether boceprevir offers added benefit in comparison with the ...
... N.Y. Researchers at Rensselaer Polytechnic Institute have developed ... disease. The surprisingly simple process was used to make ... to Alzheimer,s disease. , The process is reported in ... Proceedings of the National Academy of Sciences ( ...
... , THURSDAY, Nov. 8 (HealthDay News) -- Women aged 40 ... do themselves more harm than good, British researchers report. ... at the Wessex Institute at the University of Southampton, said ... those who receive diagnoses that turn out to be false ...
... increased in mothers postpartum, suggesting a potential new population ... cohort study. In the joint study between ... Anglia, researchers analyzed data on all women with pregnancies ... Database, which contains records from 460 practices across the ...
... Many Americans who experience acute kidney injury that does not ... year, which suggests that doctors need to do more to ... Acute kidney injury, an abrupt or rapid decline in kidney ... is caused by medical or surgical complications that deprive the ...
... Societies for Experimental Biology (FASEB) is pleased to announce ... for Glycobiology and the Society for Pediatric Research, which ... 2012. "These are very dynamic groups representing extremely important ... them as members," said FASEB President Joseph C. LaManna, ...
Cached Medicine News:Health News:Boceprevir: Indication of added benefit for specific patients 2Health News:Boceprevir: Indication of added benefit for specific patients 3Health News:Researchers design Alzheimer's antibodies 2Health News:British Study Suggests Mammograms Do More Harm Than Good 2Health News:British Study Suggests Mammograms Do More Harm Than Good 3Health News:Diagnosis of tuberculosis is increased in postpartum women 2Health News:Few With Acute Kidney Injury See Specialists, Study Finds 2
... pacemaker family, which includes the world's ... the most advanced pacemaker technology available, ... the first and only U.S. commercially ... fibrillation (AF). The AF Suppression algorithm ...
... the real-time monitoring surveillance of a ... tools. Moreover, the Information Center is ... so that monitoring data can be ... radiology images, archived data, lab results, ...
... system uses catheters that are controlled ... console. The console processes the refrigerant, ... tip of the catheter, creates cryogenic ... an easy-to-use touch-screen interface. From this ...
... tasks and delivers consistently reliable ... and ensure testing accuracy in ... automated reticulocyte counts and three-dimensional ... sensitivity, specificity and efficiency in ...
Medicine Products: